This ELISA kit uses Competitive-ELISA as the method to qualitatively detect the Anti-SARS-CoV-2 Neutralization Antibody in the sample. _x000D_ The micro ELISA plate provided in this kit is pre-coated with recombinant human ACE2. During the reaction, the SARS-CoV-2 Neutralization Antibody in the pretreated samples or controls competes with a fixed amount of human ACE2 on the solid phase supporter for sites on the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD). After 37℃ incubation, the unbound HRP-RBD as well as any HRP-RBD bound to non-Neutralization antibody will be captured on the plate and eventually form the ACE2-RBD-HRP complex, while the circulating neutralization antibodies HRP-RBD complexes remain in the supernatant and are removed during washing. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. Compared with the inhibition ratio to judge whether SARS-CoV-2 Neutralization Antibody exists in the tested samples or not.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan, China, in December 2019 This virus belongs to the Nidovirales order of the Coronaviridae family, which includes SARS-CoV and MERS-CoV, which caused outbreaks in 2003 and 2012, respectively. SARS-CoV-2 causes coronavirus disease (COVID-19) that can manifest as a severe acute respiratory syndrome. In March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. By April 2022, the total disease burden of COVID-19 was more than 500 million people, and over six million fatalities had been recorded worldwide.The serodiagnosis of the SARS-CoV-2 neutralization antibody (NAbs) needs to be explored for an accurate and reliable diagnosis.